CAJ | 학술논문

目的：评价多西紫杉醇联合FOLFOX改良方案（奥沙利铂+亚叶酸钙+替加氟）治疗晚期胃癌的近期疗效和副作用。方法选择不能手术切除或术后复发转移的晚期胃癌患者80例，随机分为实验组和对照组，各40例。实验组给予多西紫杉醇+FOLFOX改良方案化疗，对照组给予FOLFOX方案化疗，治疗2周期后评定和比较两组患者的临床疗效和不良反应。结果实验组完全缓解（CR）0例，部分缓解（PR）18例，稳定（SD）12例，进展（PD）10例，临床获益率（CBR）为75.0％，无进展生存期（PFS）7个月。对照组40例患者中， CR 0例，PR 14例，SD 13例，PD 13例，CBR为67.5％，PFS 5.5个月。两组CBR比较，差异无统计学意义（P>0.05），而实验组PFS较对照组显著延长，差异有统计学意义（P<0.05）。两组的毒性反应主要为骨髓抑制，发生率的差异无统计学意义（P>0.05）。结论多西紫杉醇联合FOLFOX改良方案治疗晚期胃癌的近期疗效尚可，不良反应患者可耐受。
목적：평개다서자삼순연합FOLFOX개량방안（오사리박+아협산개+체가불）치료만기위암적근기료효화부작용。방법선택불능수술절제혹술후복발전이적만기위암환자80례，수궤분위실험조화대조조，각40례。실험조급여다서자삼순+FOLFOX개량방안화료，대조조급여FOLFOX방안화료，치료2주기후평정화비교량조환자적림상료효화불량반응。결과실험조완전완해（CR）0례，부분완해（PR）18례，은정（SD）12례，진전（PD）10례，림상획익솔（CBR）위75.0％，무진전생존기（PFS）7개월。대조조40례환자중， CR 0례，PR 14례，SD 13례，PD 13례，CBR위67.5％，PFS 5.5개월。량조CBR비교，차이무통계학의의（P>0.05），이실험조PFS교대조조현저연장，차이유통계학의의（P<0.05）。량조적독성반응주요위골수억제，발생솔적차이무통계학의의（P>0.05）。결론다서자삼순연합FOLFOX개량방안치료만기위암적근기료효상가，불량반응환자가내수。
Objective To evaluate the clinical efficacy of docetaxel combined with FOLFOX improvement plan (oxalipl-atin+calcium+folinate+tegafur) in the treatment of advanced gastric cancer. Methods Eighty cases of patients with ad-vanced gastric carcinoma who couldn’t get resection operation or had postoperative recurrence and metastasis were selected and randomly divided into the experimental group (40 cases) and control group (40 cases). The experimental group received docetaxel+modified FOLFOX regimen chemotherapy, while the control group was given FOLFOX chemotherapy alone. After two cycles’treatment, the curative effect and incidence of adverse reactions were evaluated and compared between the two groups. Results For the experimental group, no complete remission (CR) case was observed, and partial remission (PR) was observed in 18 cases, stable disease (SD) in 12 cases, progressive disease (PD) in 10 cases. The clinical benefit rate (CR+PR+SD) was 75%, and the progression free survival (PFS) was 7 months. For the control group, PR was observed in 14 cases, SD in 13 cases, PD in 13 cases. The clinical benefit rate was 67.5%, and the PFS was 5.5 months. No statisti-cally significant difference was found in the clinical benefit rate between the two groups (P>0.05), but the PFS of experi-ment group was significantly longer than that of the control group (P<0.05). Bone marrow suppression was the main toxicity in both groups, but its incidence had no significant difference between the two groups (P>0.05). Conclusion Docetaxel combined with modified FOLFOX regimen was effective in treating patients with advanced gastric cancer, and its toxicities were tolerable.